# Growth Hormone Axis research peptides — getgoodpeptides > getgoodpeptides is a reference desk for Growth Hormone Axis research peptides — ipamorelin, CJC-1295, sermorelin, and tesamorelin — compiled from peer-reviewed literature. A digest, not a vendor or clinic. An organized briefing on four secretagogues studied for the GH/IGF-1 axis — what each does, what the studies actually measured, and where the evidence trails off. ## The short version getgoodpeptides is a reading desk, not a store. It compiles what peer-reviewed research actually says about four peptides studied for the **growth hormone axis** — ipamorelin, CJC-1295, sermorelin, and tesamorelin — and reports that research plainly, with citations, without selling anything or advising any dose. A *peptide* is a short chain of amino acids — the same molecular building blocks that make up proteins, only smaller. Each of the four covered here was designed to prod the body's own pituitary gland into releasing more growth hormone (GH). They do this not by supplying external GH directly but by nudging a receptor or two upstream. The result, when it works, is a pulse of the body's own GH — and downstream, a rise in IGF-1, the growth factor that does much of GH's work in tissues. All four operate on broadly the same axis but in different ways, with very different regulatory histories and clinical evidence bases. This guide maps those differences clearly. None of it is medical advice. We do not sell or source these compounds. ## What is the GH axis, and why do these peptides target it? Growth hormone (GH) is released in pulses by the anterior pituitary gland, principally during deep sleep and exercise. Its main downstream signal is IGF-1 (insulin-like growth factor 1), produced mainly by the liver. Together, GH and IGF-1 regulate lean body mass, bone density, fat distribution, and energy metabolism throughout adulthood. GH release is controlled by two opposing hypothalamic signals. Growth hormone-releasing hormone (GHRH) pushes the pituitary to fire a GH pulse. Somatostatin quiets it again. The peptides on this desk work within this system: - **Ipamorelin** is a *growth hormone secretagogue receptor agonist* (GHS-R1a) — it mimics ghrelin, the gut-derived hunger hormone, and triggers GH release from a receptor distinct from the GHRH receptor. It produces a clean, discrete GH pulse [6]. - **CJC-1295** is a *GHRH analog* that binds the GHRH receptor directly and, in its long-acting (DAC) form, sustains stimulation for days via albumin-binding chemistry [11]. - **Sermorelin** is the original 29-amino-acid GHRH fragment, matching the shortest fully active portion of natural GHRH, previously approved as a drug for pediatric GH deficiency [8]. - **Tesamorelin** is a full-length 44-amino-acid GHRH analog, FDA-approved for a specific HIV-related indication, with the most robust human evidence of the four [17][18]. All four preserve the pituitary's natural feedback loop — somatostatin can still slow the response, and IGF-1 can still signal the system to back off — which is the key mechanistic contrast with injecting recombinant GH directly [8]. ## Four secretagogues, four evidence profiles Reading across the four compounds gives a fast sense of the evidence landscape: **Ipamorelin** has the cleanest preclinical selectivity data [6] and the most-discussed community reports, but its only published Phase 2 RCT missed its primary endpoint [3]. Its GH-axis mechanism is distinct from the GHRH-receptor compounds. **CJC-1295** has solid early human pharmacokinetic data showing sustained GH and IGF-1 elevation [11][12], but its development program was halted and it has never been approved. The DAC and no-DAC forms are frequently conflated but behave very differently in duration. **Sermorelin** carries the oldest and most structured clinical record — it was once an FDA-approved drug for pediatric GH deficiency [16], was voluntarily withdrawn for commercial reasons in 2008, and is now available under 503A compounding. A 2008 editorial concluded GH secretagogue anti-aging use is "not yet ready for prime time" [14]. **Tesamorelin** stands apart: it is the only compound here with completed Phase 3 trials and a current FDA approval — though that approval is specifically for HIV-associated lipodystrophy [18]. Multiple RCTs confirm visceral fat reduction in that population [17][19][21]; all other uses are off-label and investigational. A side-by-side comparison of all four is on the [Compare](/compare) page. Individual deep-dives are on each compound's page. ## How this desk reads the literature getgoodpeptides is a cross-referenced literature digest. Each compound page covers mechanism, key study findings (with species noted), reported effects (labeled anecdotal where they are), safety cautions grounded in the published evidence, and regulatory status. Where evidence is preclinical only, or limited to single-lab rodent data, we say so. Where claims circulate in research-use communities without clinical support, we include them clearly labeled **"anecdotal, not clinical evidence."** We do not guess at dose recommendations, we do not aggregate testimonials as proof, and we do not sell anything. The [references](/references) page lists every cited source. All four compounds are banned in sport under WADA S2 at all times. All but tesamorelin (in its approved HIV indication) lack regulatory approval for general human use. These are the facts; they belong in any honest briefing on this class. --- An independent literature digest of peer-reviewed research on the GH/IGF-1 axis — organized like a clinician's briefing, not a product catalog.